IRIS – Institutional Research Information System
IRIS è il sistema di gestione della ricerca dell’Università degli Studi di Milano-Bicocca.Il repository BOA è il modulo del sistema dedicato alla raccolta e alla disseminazione della produzione scientifica di Ateneo. Le pubblicazioni sono ricercabili per parola chiave attraverso il box nella barra orizzontale in alto oppure, mediante il pulsante Sfoglia, per "Afferenza", "Autore", "Titolo", "Tipologia" o "Settore scientifico-disciplinare".
IRIS contiene inoltre alcuni moduli dedicati alla registrazione dei progetti e dei contratti, e alla reportistica avanzata per le attività di valutazione della ricerca
EnglishOBJECTIVE: The recombinant fusion protein, aflibercept binds and neutralizes vascular endothelial growth factor (VEGF) A, B and placental growth factor (PlGF). Aflibercept inhibits ascites formation and reduces tumor burden in an ovarian cancer model. This open-label, single-arm, multicenter phase II study assessed the efficacy and safety of aflibercept in patients with advanced chemo-resistant epithelial ovarian cancer and symptomatic malignant ascites. METHODS: Patients who required≥3 previous paracenteses at 1-4 paracenteses per month received intravenous aflibercept 4mg/kg every 2weeks. The primary endpoint was repeat paracentesis response rate (RPRR), with response defined as at least a two-fold increase in time to repeat paracentesis compared with the baseline interval. RESULTS: Ten out of 16 enrolled patients achieved a response; the RPRR was 62.5% (95% CI 35.4%-84.8%). Aflibercept was considered effective based on a hypothesis that the RPRR was ≥60%. Median time to repeat paracentesis was 76.0 (95% CI 64.0-178.0) days, which was 4.5 times longer than the baseline interval (16.8days). Median progression-free survival was 59.5 (95% CI 41.0-83.0) days. Twelve patients experienced adverse events considered related to aflibercept treatment including hypertension (7 patients), headache, anorexia, and dysphonia (3 patients each). Two patients experienced Grade 3/4 treatment-related adverse events (Grade 3 hypertension and weight loss in one patient, Grade 3 intestinal perforation in one patient). CONCLUSION: Aflibercept 4mg/kg every 2weeks was effective at controlling malignant ascites, reducing the interval between repeat paracenteses. The safety profile was consistent with that reported for anti-VEGF agents.
Colombo, N., Mangili, G., Mammoliti, S., Kalling, M., Tholander, B., Sternas, L., et al. (2011). A phase II study of aflibercept in patients with advainced epithelial ovarian cancer and symptomatic malignant ascites. GYNECOLOGIC ONCOLOGY.
| Citazione: | Colombo, N., Mangili, G., Mammoliti, S., Kalling, M., Tholander, B., Sternas, L., et al. (2011). A phase II study of aflibercept in patients with advainced epithelial ovarian cancer and symptomatic malignant ascites. GYNECOLOGIC ONCOLOGY. |
| Tipo: | Articolo in rivista - Articolo scientifico |
| Carattere della pubblicazione: | Scientifica |
| Presenza di un coautore afferente ad Istituzioni straniere: | No |
| Titolo: | A phase II study of aflibercept in patients with advainced epithelial ovarian cancer and symptomatic malignant ascites |
| Autori: | Colombo, N; Mangili, G; Mammoliti, S; Kalling, M; Tholander, B; Sternas, L; Buzenet, G; Chamberlain, D |
| Autori: | |
| Data di pubblicazione: | 20-nov-2011 |
| Lingua: | English |
| Rivista: | GYNECOLOGIC ONCOLOGY |
| Digital Object Identifier (DOI): | http://dx.doi.org/10.1016/j.ygyno.2011.11.021 |
| Appare nelle tipologie: | 01 - Articolo su rivista |
File in questo prodotto:
Copyright © 2021